Enhancing Antiproliferative Activity and Selectivity of a FLT-3 Inhibitor by Proteolysis Targeting Chimera Conversion

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• FMS-like tyrosine kinase 3 (FLT-3) mutations are common in acute myeloid leukemia (AML).
• Existing FLT-3 inhibitors show limited clinical effectiveness.
• Targeting FLT-3 degradation offers a potential therapeutic avenue.

Purpose of the Study:

• To develop and evaluate a proteolysis targeting chimera (PROTAC) for FLT-3 mutant degradation.
• To assess the efficacy of the PROTAC compared to the parent inhibitor.
• To investigate the mechanism of enhanced anti-leukemic activity.

Main Methods:

• Chemical synthesis of a quizartinib-based PROTAC.
• In vitro assessment of FLT-3 ITD degradation and kinase inhibition.
• Cell proliferation and apoptosis assays.
• In vivo studies in relevant models.

Main Results:

• The PROTAC efficiently degraded FLT-3 ITD mutant at low nanomolar concentrations.
• PROTAC exhibited superior antiproliferative effects and induced more apoptosis than the inhibitor alone.
• PROTAC showed reduced off-target kinase inhibition.
• In vivo degradation of FLT-3 ITD was achieved.

Conclusions:

• PROTAC-mediated degradation of FLT-3 ITD is a potent anti-leukemic strategy.
• This approach overcomes limitations of traditional FLT-3 inhibitors.
• Degradation of FLT-3 ITD may target non-kinase functions, enhancing therapeutic potential.